Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.48 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14488389 | 0.86 | SIGMAR1 (0.59) | SIGMAR1HRH3ADRA1DADRA1AADRA1B | |
| SCHEMBL14486458 | 0.85 | SIGMAR1 (0.58) | SIGMAR1HRH3ADRA1DADRA1AADRA1B | |
| SCHEMBL14486421 | 0.85 | SIGMAR1 (0.52) | SIGMAR1HRH3ADRA1DADRA1AADRA1B | |
| SCHEMBL14486427 | 0.84 | SIGMAR1 (0.51) | SIGMAR1HRH3ADRA1DADRA1AADRA1B | |
| SCHEMBL14486442 | 0.83 | ADRA1D (0.51) | SIGMAR1HRH3ADRA1DADRA1AADRA1B | |
| SCHEMBL14698978 | 0.83 | SIGMAR1 (0.56) | SIGMAR1HRH3ADRA1DADRA1AADRA1B | |
| SCHEMBL14697929 | 0.83 | SIGMAR1 (0.56) | SIGMAR1HRH3ADRA1DADRA1AADRA1B | |
| SCHEMBL14697894 | 0.82 | SIGMAR1 (0.54) | SIGMAR1HRH3ADRA1DADRA1AADRA1B | |
| SCHEMBL14486356 | 0.81 | SIGMAR1 (0.48) | SIGMAR1HRH3ADRA1DADRA1AADRA1B | |
| SCHEMBL14486549 | 0.81 | FAAH (0.48) | SIGMAR1HRH3ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023852-B2 | 1, 2, 4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | REMYND NV (BE) | 2015-05-05 | — | — | US | disclosed |
| EP-2726470-B1 | 1,2,4-THIADIAZOL-5-YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2015-04-29 | — | — | EP | disclosed |
| US-20140128404-A1 | 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | REMYND NV (BE) | 2014-05-08 | — | — | US | disclosed |
| EP-2726470-A1 | 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES | reMynd NV (BE) | 2014-05-07 | — | — | EP | disclosed |
| WO-2013004642-A1 | 1, 2, 4 -THIADIAZOL- 5 -YLPIPERAZINE DERIVATIVES USEFUL IN THE TREATMENT NEURODEGENERATIVE DISEASES | REMYND NV (BE) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128404-A1 | 1, 2, 4-Thiadiazol-5-Ylpiperazine derivatives useful in the treatment of neurodegenerative diseases | MAPT, PSEN1, PSEN2 | SIGMAR1 2467/4885HRH3 3735/4885ADRA1D 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.